Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
The Journal of Biological Chemistry|June 5, 1992
Translocation of preproinsulin across the endoplasmic reticulum membrane. The relationship between nascent polypeptide size and extent of signal recognition particle-mediated inhibition of protein synthesisM M Okun, D ShieldsClinical and Experimental Dermatology|May 1, 1994
A quinine-induced drug reaction of photosensitive distribution with histological features mimicking mycosis fungoidesM M Okun, M Henner, C PaulsonThe Journal of Biological Chemistry|May 5, 1990
Truncations of a secretory protein define minimum lengths required for binding to signal recognition particle and translocation across the endoplasmic reticulum membraneM M Okun, E M Eskridge, D ShieldsJournal of Molecular Endocrinology|March 1, 1989
In-vitro biosynthesis of multiple preproglucagons results from acetylation of the primary translation productsM M Okun, T G Warren, D ShieldsThe British Journal of Dermatology|April 17, 2010
Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasisR G Langley, B E Strober, Y Gu, et al.The British Journal of Dermatology|May 9, 2012
Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label studyC Leonardi, J M Sobell, J J Crowley, et al.Journal of Virology|April 5, 2001
L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidationM M Okun, P M Day, H L Greenstone, et al.The British Journal of Dermatology|August 18, 2012
Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trialB E Strober, J M Sobell, K C Duffin, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|July 16, 2019
Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trialB E Elewski, C S Baker, J J Crowley, et al.The British Journal of Dermatology|July 22, 2014
Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatmentA B Kimball, G B E Jemec, M Yang, et al.Pageof 2